Updates on first-line therapy for metastatic pancreatic adenocarcinoma

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 99-102

  Marks, Eric ^a   Saif, Muhammad Wasif ^b   Jia, Yuxia ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Drug Therapy; Immunotherapy; Neoplasm Metastasis; Pancreatic Neoplasms

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEPARIN; IRINOTECAN; LENALIDOMIDE; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ANEMIA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNE RESPONSE; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERFORMANCE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84897823944     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2279     Document Type: Conference Paper

References (9)

1. Cancer Facts and Figures 2013. 2013, American Cancer Society: Atlanta.
2. SEER Cancer Statistics Review. Surveillance, Epidemiology, and End Results Program, 2013.
3. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, in www.nccn.org. 2014.
4. Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol, 2012. 18(8): p. 736-45. [PMID 22371633]
5. Nemunaitis J., Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines, 2005. 4(3): p. 259-74. [PMID 16026242]
6. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi TS, Springett GM, et al., A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX along in patients with metastatic pancreatic adenocarcinoma: Updated results. J Clin Oncol 2014; 32(Suppl 3): Abstract 177.
7. Goldstein D, El Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al., Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. J Clin Oncol 2014; 32(Suppl 3): Abstract 178.
8. Ramanathan R, Lee P, Seng J, Anthony SP, Rosen PJ, Mena RR, et al., Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. J Clin Oncol 2014; 32(Suppl 3): Abstract 224.
9. Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013 Dec;32(3-4):585- 602.